Results 191 to 200 of about 73,005 (301)
Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma +9 more
wiley +1 more source
Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou +6 more
wiley +1 more source
Pre and post introduction of pneumococcal conjugate vaccines in children in Eastern Mediterranean Region and effect on antimicrobial resistance, a narrative review. [PDF]
Saleh BM, Mere O, Elmrayed S.
europepmc +1 more source
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao +4 more
wiley +1 more source
Double-hit approach for novel glycoconjugates combining cytoplasmic glycoengineering and selective chemistry. [PDF]
Palmieri E +5 more
europepmc +1 more source
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu +7 more
wiley +1 more source
Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial. [PDF]
Thuluva S +14 more
europepmc +1 more source
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik +3 more
wiley +1 more source

